Search Results
The Molecular Tumor Board: Best Practices for Managing Primary and Acquired EGFR TKI Resistance
TKI-resistant EGFR-mutant NSCLC
GRACEcast-088_Lung-Cancer_Challenging Cases in Lung Cancer: Acquired Resistance to EGFR TKI Therapy
Optimizing Advanced NSCLC Biomarker Testing, Treatment and Management Session 1
Time for Even More Precision in Testing and Treatment of EGFR-Mutated NSCLC
Long Term Management of EGFR-Mutant NSCLC -Tsao
Mutation Based Resistance to TKI Therapy - by Frank G. Haluska, MD, PhD
Case 4: Metastatic EGFR+ NSCLC Progressing on Osimertinib
Data + Perspectives: Clinical Investigators Explore the Application of Recent Datasets in Current...
Lung Cancer | Striving for Consensus on the Management of ALK-Positive Lung Cancer
Yale Cancer Center Grand Rounds | June 22, 2021
ILCN Multidisciplinary Forum: Understanding Treatment Options and Resistance in EGFR-positive NSCLC
